Walid Macaron
Overview
Explore the profile of Walid Macaron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Venugopal S, DiNardo C, Loghavi S, Qiao W, Ravandi F, Konopleva M, et al.
Am J Hematol
. 2022 Sep;
97(12):1560-1567.
PMID: 36087091
RUNX1-mutated (mRUNX1) acute myeloid leukemia (AML) has historically been associated with poor outcomes in the setting of conventional chemotherapy. The prognostic impact of mRUNX1 AML is not well-established in the...
12.
Short N, Macaron W, Kadia T, DiNardo C, Issa G, Daver N, et al.
Am J Hematol
. 2022 Sep;
97(11):E408-E411.
PMID: 36054774
Recurrence of MRD in AML is associated with imminent relapse unless intervened upon. Change in chemotherapy regimen and/or immediate transplant improve outcomes.
13.
Desikan S, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour E, et al.
Acta Haematol
. 2022 Jun;
145(5):529-536.
PMID: 35717939
Introduction: RAS pathway mutations are common mechanisms of resistance to acute myeloid leukemia (AML) therapies. Trametinib, an oral MEK inhibitor, has been shown to have single-agent activity in relapsed/refractory AML...
14.
Short N, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, et al.
Blood Adv
. 2022 May;
6(13):4006-4014.
PMID: 35533262
Measurable residual disease (MRD) is highly prognostic for relapse and overall survival (OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent "MRD negativity" by standard assays still relapse....
15.
Short N, Borthakur G, Pemmaraju N, DiNardo C, Kadia T, Jabbour E, et al.
Leuk Lymphoma
. 2022 Apr;
63(9):2161-2170.
PMID: 35442137
We conducted a phase Ib/II multi-arm, parallel cohort study to simultaneously evaluate various immunotherapeutic agents and combinations in relapsed/refractory acute myeloid leukemia (AML). Overall, 50 patients were enrolled into one...
16.
El Gharib K, Macaron W, Kattan J, Salloum M, Farhat F, Smith M, et al.
Curr Probl Cancer
. 2022 Apr;
46(3):100859.
PMID: 35378469
CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules...
17.
Macaron W, Sargsyan Z, Short N
Leuk Lymphoma
. 2022 Mar;
63(8):1780-1791.
PMID: 35357988
Leukostasis is a life-threatening complication of high concentrations of circulating leukemic cells, most often myeloblasts. Effective care of patients with leukostasis involves early recognition and treatment, and aggressive management of...
18.
Short N, Macaron W, Konopleva M, Ravandi F, Jain N, Issa G, et al.
Am J Hematol
. 2022 Mar;
97(6):E201-E204.
PMID: 35266566
No abstract available.
19.
Short N, Venugopal S, Qiao W, Kadia T, Ravandi F, Macaron W, et al.
J Hematol Oncol
. 2022 Jan;
15(1):12.
PMID: 35093134
Background: Treated secondary acute myeloid leukemia (ts-AML)-i.e., AML arising from a previously treated antecedent hematologic disorder-is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is...